Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2020 / N 4

Новые возможности в лечении пациентов с гриппом: препарат балоксавир марбоксил
В.Н. Ларина, В.П. Чуланов

Список литературы

1. Никифоров В.В., Колобухина Л.В., Суранова Т.Г., Сметанина С.В., Кардонова Е.В., Бурова С.В., Томилин Ю.Н., Серова М.А., Янковская Я.Д. Грипп и острые респираторные вирусные инфекции: современная рациональная этиотропная и патогенетическая терапия. Алгоритмы оказания медицинской помощи больным. Методические рекомендации. М.: Спецкнига; 2018. 20 с.
2. Зарубаев В.В., Слита А.В., Синегубова Е.О., Мурылева А.А., Лаврентьева И.Н. Противовирусная активность энисамия йодида в отношении вирусов гриппа и ОРВИ in vitro на различных клеточных линиях. Терапевтический архив 2020;92(11):45-50.
3. Centers for Disease Control and Prevention. Disease burden of influenza. Available from: https://www.cdc.gov/flu/about/burden/index.html Accessed 2021 Feb 11.
4. Понежева Ж.Б., Купченко А.Н., Маннанова И.В., Горелов А.В. Интерфероны и противовирусный иммунитет. Эффективная фармакотерапия 2018;14:14-21.
5. Steel J, Lowen AC. Influenza A virus reassortment. Current Topics in Microbiology and Immunology 2014;385:377-401.
6. Khandaker GM, Barnett JH, White IR, Jones PB. A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia. Schizophrenia Research 2011 Nov;132(2-3):220-7.
7. Influenza and other respiratory viruses: surveillance in the Americas 2019. Washington, D.C.: Pan American Health Organization; 2020. 136 p.
8. Clar C, Oseni Z, Flowers N, Keshtkar‐Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. The Cochrane Database of Systematic Reviews 2015 May;(5):CD005050.
9. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, Ciszewski A, Vakili H, Hoffman EB, Farkouh ME, Cannon CP. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013 Oct;310(16):1711-20.
10. World Health Organization. Influenza (seasonable). Available from: http://www.who.int/mediacentre/factsheets/fs211/en/ Accessed 2021 Feb 11.
11. Centers for Disease Control and Prevention. Vaccines effectiveness: how well the flu vaccines work? Questions and answers. Available from: https://www.cdc.gov/flu/about/qa/vaccineeffect.htm Accessed 2021 Feb 11.
12. Львов Д.К., Колобухина Л.В., Бурцева Е.И., Кружкова И.С., Малышев Н.А., Федякина И.Т., Кириллова Е.С., Трушакова С.В., Фодоритова Е.Л., Меркулова Л.Н., Краснослободцева К.Г., Мукашева Е.А., Гарина Е.О., Вартанян Р.В., Кистенева Л.Б., Прилипов А.Г., Базарова М.В., Девяткин А.В., Суточникова О.А. Эпидемический сезон 2015–2016 г. в России и мире: особенности циркуляции вирусов гриппа, динамика заболеваемости, клинические аспекты и алгоритм лечения. Терапевтический архив 2016;88(11):112-20.
13. Ларина В.Н., Захарова М.И., Беневская В.Ф., Головко М.Г, Соловьев С.С. Острые респираторные вирусные инфекции и грипп: этиология, диагностика и алгоритм лечения. Русский медицинский журнал 2019;9(I):18-23.
14. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TSA, Al Mamun A, Anovadiya AP, Azziz-Baumgartner E, Báez C, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Denholm JT, Dominguez SR, Duarte PAD, Dubnov-Raz G, Echavarria M, Fanella S, Gao Z, Gérardin P, Giannella P, Gubbels S, Herberg J, Higuera Iglesias AL, Hoger PH, Hu X, Islam QT, Jiménez MF, Kandeel A, Keijzers G, Khalili H, Knight M, Kudo K, Kusznierz G, Kuzman I, Kwan AMC, Amine IL, Langenegger E, Lankarani KB, Leo YS, Linko R, Liu P, Madanat F, Mayo-Montero E, McGeer A, Memish Z, Metan G, Mickiene A, Mikić D, Mohn KGI, Moradi A, Nymadawa P, Oliva ME, Ozkan M, Parekh D, Paul M, Polack FP, Rath BA, Rodríguez AH, Sarrouf EB, Seale AC, Sertogullarindan B, Siqueira MM, Skręt-Magierło J, Stephan F, Talarek E, Tang JW, To KKW, Torres A, Törün SH, Tran D, Uyeki TM, Van Zwol A, Vaudry W, Vidmar T, Yokota RTC, Zarogoulidis P; PRIDE Consortium Investigators; Nguyen-Van-Tam JS. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. The Lancet. Respiratory Medicine 2014 May;2(5):395-404.
15. O’Hanlon R, Shaw ML. Baloxavir marboxil: the new influenza drug on the market. Current Opinion in Virology 2019 Apr;35:14-8.
16. U.S. Food & Drug Administration. FDA news release. FDA expands approval of influenza treatment to post-exposure prevention. November 23, 2020. Available from: https://www.fda.gov/news-events/press-announcements/fda-expands-approval-influenza-treatment-post-exposure-prevention Accessed 2021 Feb 11.
17. Пшеничная Н.Ю., Булгакова В.А., Волчкова Е.В., Карева Е.Н., Селькова Е.П., Городин В.Н. Обзор текущих и перспективных направлений противовирусной терапии гриппа и острых респираторных вирусных инфекций в России. Терапевтический архив 2019;91(11):105-9.
18. Bragstad K, Hungnes O, Litleskare I, Nyrerød HC, Dorenberg DH, Hauge SH. Community spread and late season increased incidence of oseltamivir-resistant influenza A(H1N1) viruses in Norway 2016. Influenza and Other Respiratory Viruses 2019 Jul;13(4):372-81.
19. Лиознов Д.А., Карнаухова Е.Ю., Зубкова Т.Г., Шахланская Е.В. Оценка эффективности схемы лечения ОРВИ, включающей этиотропную (энисамия йодид) и симптоматическую терапию. Терапевтический архив 2020;92(3):50-5.
20. Министерство здравоохранения РФ. Клинические рекомендации. Грипп у взрослых. МКБ 10: J10/ J11. Год утверждения (частота пересмотра): 2017 (пересмотр каждые 3 года). М., 57 с.
21. U.S. Food & Drug Administration. FDA news release. FDA approves new drug to treat influenza. October 24, 2018. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-influenza Accessed 2021 Feb 11.
22. Kawai M, Tomita K, Akiyama T, Okano A, Miyagawa M. 2016. Substituted polycyclic pyridone derivative and prodrug thereof (patent WO2016175224A1). Available from: https://patentscope2.wipo.int/search/en/detail.jsf?docId=WO2016175224 Accessed 2021 Feb 11.
23. Heo YA. Baloxavir: first global approval. Drugs 2018;78(6):693-7.
24. АО «РОШ-Москва». Пресс-релиз. В России зарегистрирован инновационный препарат для лечения гриппа. Доступно по: https://www.roche.ru/content/dam/rochexx/roche-ru/roche_russia/ru_RU/PDF_news/release-xofluza-approval-2020-09-25.pdf Ссылка активна на 11.02.2021.
25. Baker DE. Baloxavir marboxil. Hospital Pharmacy 2019 Jun;54(3):165-9.
26. Инструкция по медицинскому применению препарата Ксофлюза. Регистрационный номер ЛП-006451.
27. Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, Hashimoto T, Ishida K, Kushima Y, Hattori K, Kawai M, Yoshida R, Kobayashi M, Yoshinaga T, Sato A, Okamatsu M, Sakoda Y, Kida H, Shishido T, Naito A. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Research 2018 Dec;160:109-17.
28. Shaw ML. The next wave of influenza drugs. ACS Infectious Diseases 2017 Oct;3(10):691-4.
29. Fukao K, Ando Y, Noshi T, Kitano M, Noda T, Kawai M, Yoshida R, Sato A, Shishido T, Naito A. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. PLoS One 2019 May;14(5):e0217307.
30. Fukao K, Noshi T, Yamamoto A, Kitano M, Ando Y, Noda T, Baba K, Matsumoto K, Higuchi N, Ikeda M, Shishido T, Naito A. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. The Journal of Antimicrobial Chemotherapy 2019 May;74(3):654-62.
31. Kawaguchi N, Koshimichi H, Ishibashi T, Wajima T. Evaluation of drug-drug interaction potential between baloxavir marboxil and oseltamivir in healthy subjects. Clinical Drug Investigation 2018 Nov;38(11):1053-60.
32. Koshimichi H, Ishibashi T, Kawaguchi N, Sato C, Kawasaki A, Wajima T. Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings. Clinical Drug Investigation 2018 Dec;38(12):1189-96.
33. Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. The New England Journal of Medicine 2018 Sep;379(10):913-23.
34. Ison MG, Portsmouth S, Yoshida Y, Shishido T, Hayden F, Uehara T. LB16. Phase 3 trial of baloxavir marboxil in high-risk influenza patients (CAPSTONE-2 study). Open Forum Infectious Diseases 2018 Nov;5(Suppl 1):S764-5.
35. Shirley M. Baloxavir marboxil: a review in acute uncomplicated influenza. Drugs 2020 Jul;80(11):1109-18.
36. Тайеб В., Икеока Х., Ма Ф., Борковска К., Абальеа С., Тон К., Хироцу Н. Сетевой метаанализ эффективности и безопасности балоксавира марбоксила в сравнении с ингибиторами нейраминидазы при лечении гриппа у пациентов без факторов риска. Терапевтический архив 2020;92(11):122-31.

References

1. Nikiforov VV, Kolobukhina LV, Suranova TG, Smetanina SV, Cardonova EV, Burova SV, Tomilin YuN, Serova MA, Yankovskaya YaD. Influenza and acute respiratory viral infections: current rational etiotropic and pathogenetic therapy. Algorithms for providing medical care to patients: methodological recommendations. Moscow: Spetskniga; 2018. 20 p. (In Russian).
2. Zarubayev VV, Slita AV, Sinegubova EO, Muryleva AA, Lavrentyeva IN. Anti-viral activity of enisamium iodide against viruses of influenza and ARVI on different cell lines. Therapeutic Archive 2020;92(11):45-50 (In Russian).
3. Centers for Disease Control and Prevention. Disease burden of influenza. Available from: https://www.cdc.gov/flu/about/burden/index.html Accessed 2021 Feb 11.
4. Ponezheva ZhB, Kupchenko AN, Mannanova IV, Gorelov AV. Interferons and antiviral immunity. Effective Pharmaсotherapy 2018;1(14):14-21 (In Russian).
5. Steel J, Lowen AC. Influenza A virus reassortment. Current Topics in Microbiology and Immunology 2014;385:377-401.
6. Khandaker GM, Barnett JH, White IR, Jones PB. A quantitative meta-analysis of population-based studies of premorbid intelligence and schizophrenia. Schizophrenia Research 2011 Nov;132(2-3):220-7.
7. Influenza and other respiratory viruses: surveillance in the Americas 2019. Washington, D.C.: Pan American Health Organization; 2020. 136 p.
8. Clar C, Oseni Z, Flowers N, Keshtkar‐Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. The Cochrane Database of Systematic Reviews 2015 May;(5):CD005050.
9. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, Ciszewski A, Vakili H, Hoffman EB, Farkouh ME, Cannon CP. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013 Oct;310(16):1711-20.
10. World Health Organization. Influenza (seasonable). Available from: http://www.who.int/mediacentre/factsheets/fs211/en/ Accessed 2021 Feb 11.
11. Centers for Disease Control and Prevention. Vaccines effectiveness: how well the flu vaccines work? Questions and answers. Available from: https://www.cdc.gov/flu/about/qa/vaccineeffect.htm Accessed 2021 Feb 11.
12. Lvov DK, Kolobukhina LV, Burtseva EI, Kruzhkova IS, Malyshev NA, Fedyakina IT, Kirillova ES, Trushakova SV, Fodoritova EL, Merkulova LN, Krasnoslobodtseva KG, Mukasheva EA, Garina EO, Vartanyan RV, Kisteneva LB, Prilipov AG, Bazarova MV, Devyatkin AV, Sutochnikova OA. The 2015–2016 epidemic season in Russia and in the world: circulation of influenza viruses, trends in incidence, clinical aspects, and treatment algorithm. Therapeutic Archive 2016;88(11):112-20 (In Russian).
13. Larina VN, Zakharova MI, Benevskaya VF, Golovko MG, Solovyev SS. Acute respiratory viral infections and influenza: etiology, diagnosis, and treatment algorithm. Russian Medical Journal 2019;9(I):18-23 (In Russian).
14. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TSA, Al Mamun A, Anovadiya AP, Azziz-Baumgartner E, Báez C, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Denholm JT, Dominguez SR, Duarte PAD, Dubnov-Raz G, Echavarria M, Fanella S, Gao Z, Gérardin P, Giannella P, Gubbels S, Herberg J, Higuera Iglesias AL, Hoger PH, Hu X, Islam QT, Jiménez MF, Kandeel A, Keijzers G, Khalili H, Knight M, Kudo K, Kusznierz G, Kuzman I, Kwan AMC, Amine IL, Langenegger E, Lankarani KB, Leo YS, Linko R, Liu P, Madanat F, Mayo-Montero E, McGeer A, Memish Z, Metan G, Mickiene A, Mikić D, Mohn KGI, Moradi A, Nymadawa P, Oliva ME, Ozkan M, Parekh D, Paul M, Polack FP, Rath BA, Rodríguez AH, Sarrouf EB, Seale AC, Sertogullarindan B, Siqueira MM, Skręt-Magierło J, Stephan F, Talarek E, Tang JW, To KKW, Torres A, Törün SH, Tran D, Uyeki TM, Van Zwol A, Vaudry W, Vidmar T, Yokota RTC, Zarogoulidis P; PRIDE Consortium Investigators; Nguyen-Van-Tam JS. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. The Lancet. Respiratory Medicine 2014 May;2(5):395-404.
15. O’Hanlon R, Shaw ML. Baloxavir marboxil: the new influenza drug on the market. Current Opinion in Virology 2019 Apr;35:14-8.
16. U.S. Food & Drug Administration. FDA news release. FDA expands approval of influenza treatment to post-exposure prevention. November 23, 2020. Available from: https://www.fda.gov/news-events/press-announcements/fda-expands-approval-influenza-treatment-post-exposure-prevention Accessed 2021 Feb 11.
17. Pshenichnaya NYu, Bulgakova VA, Volchkova EV, Kareva EN, Selkova EP, Gorodin VN. Review of current and future directions of antiviral therapy of influenza and acute respiratory viral infections in Russia. Therapeutic Archive 2019;91(11):105-9 (In Russian).
18. Bragstad K, Hungnes O, Litleskare I, Nyrerød HC, Dorenberg DH, Hauge SH. Community spread and late season increased incidence of oseltamivir-resistant influenza A(H1N1) viruses in Norway 2016. Influenza and Other Respiratory Viruses 2019 Jul;13(4):372-81.
19. Lioznov DA, Karnaukhova EYu, Zubkova TG, Shakhlanskaya EV. Efficacy of the scheme for treatment of SARS, including causal (anosmia iodide) and symptomatic therapy. Therapeutic Archive 2020;92(3):50-5 (In Russian).
20. Ministry of Health of the Russian Federation. Clinical recommendations. Flu in adults. ICD 10: J10/ J11. Year of approval: 2017. Moscow, 57 p. (In Russian).
21. U.S. Food & Drug Administration. FDA news release. FDA approves new drug to treat influenza. October 24, 2018. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-influenza Accessed 2021 Feb 11.
22. Kawai M, Tomita K, Akiyama T, Okano A, Miyagawa M. 2016. Substituted polycyclic pyridone derivative and prodrug thereof (patent WO2016175224A1). Available from: https://patentscope2.wipo.int/search/en/detail.jsf?docId=WO2016175224 Accessed 2021 Feb 11.
23. Heo YA. Baloxavir: first global approval. Drugs 2018;78(6):693-7.
24. JSC "Roche-Moscow". Press release. An innovative drug for treatment of influenza has been registered in Russia. Available from: https://www.roche.ru/content/dam/rochexx/roche-ru/roche_russia/ru_RU/PDF_news/release-xofluza-approval-2020-09-25.pdf Accessed 2021 Feb 11. (In Russian).
25. Baker DE. Baloxavir marboxil. Hospital Pharmacy 2019 Jun;54(3):165-9.
26. Instructions for the medical use of Xofluza drug. Registration number LP-006451 (In Russian).
27. Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K, Hashimoto T, Ishida K, Kushima Y, Hattori K, Kawai M, Yoshida R, Kobayashi M, Yoshinaga T, Sato A, Okamatsu M, Sakoda Y, Kida H, Shishido T, Naito A. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Research 2018 Dec;160:109-17.
28. Shaw ML. The next wave of influenza drugs. ACS Infectious Diseases 2017 Oct;3(10):691-4.
29. Fukao K, Ando Y, Noshi T, Kitano M, Noda T, Kawai M, Yoshida R, Sato A, Shishido T, Naito A. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models. PLoS One 2019 May;14(5):e0217307.
30. Fukao K, Noshi T, Yamamoto A, Kitano M, Ando Y, Noda T, Baba K, Matsumoto K, Higuchi N, Ikeda M, Shishido T, Naito A. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. The Journal of Antimicrobial Chemotherapy 2019 May;74(3):654-62.
31. Kawaguchi N, Koshimichi H, Ishibashi T, Wajima T. Evaluation of drug-drug interaction potential between baloxavir marboxil and oseltamivir in healthy subjects. Clinical Drug Investigation 2018 Nov;38(11):1053-60.
32. Koshimichi H, Ishibashi T, Kawaguchi N, Sato C, Kawasaki A, Wajima T. Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase I study findings. Clinical Drug Investigation 2018 Dec;38(12):1189-96.
33. Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. The New England Journal of Medicine 2018 Sep;379(10):913-23.
34. Ison MG, Portsmouth S, Yoshida Y, Shishido T, Hayden F, Uehara T. LB16. Phase 3 trial of baloxavir marboxil in high-risk influenza patients (CAPSTONE-2 study). Open Forum Infectious Diseases 2018 Nov;5(Suppl 1):S764-5.
35. Shirley M. Baloxavir marboxil: a review in acute uncomplicated influenza. Drugs 2020 Jul;80(11):1109-18.
36. Taieb V, Ikeoka H, Ma FF, Borkowska K, Aballéa S, Tone K, Hirotsu N. A network meta-analysis of efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for treatment of influenza in otherwise healthy patients. Therapeutic Archive 2020;92(11):122-31 (In Russian).
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]